Logo image of KNE.CA

KANE BIOTECH INC (KNE.CA) Stock Fundamental Analysis

Canada - TSX-V:KNE - CA4838092084 - Common Stock

0.04 CAD
0 (0%)
Last: 11/14/2025, 7:00:00 PM
Fundamental Rating

2

KNE gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 22 industry peers in the Biotechnology industry. KNE may be in some trouble as it scores bad on both profitability and health. KNE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

KNE had negative earnings in the past year.
In the past year KNE has reported a negative cash flow from operations.
KNE had negative earnings in 4 of the past 5 years.
KNE had a negative operating cash flow in each of the past 5 years.
KNE.CA Yearly Net Income VS EBIT VS OCF VS FCFKNE.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M -4M 6M

1.2 Ratios

The Return On Assets of KNE (-87.22%) is better than 63.64% of its industry peers.
Industry RankSector Rank
ROA -87.22%
ROE N/A
ROIC N/A
ROA(3y)28.88%
ROA(5y)-12.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KNE.CA Yearly ROA, ROE, ROICKNE.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K 20K 30K 40K 50K

1.3 Margins

KNE has a Gross Margin of 25.34%. This is in the better half of the industry: KNE outperforms 72.73% of its industry peers.
KNE's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for KNE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 25.34%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.83%
GM growth 5Y3.08%
KNE.CA Yearly Profit, Operating, Gross MarginsKNE.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

2

2. Health

2.1 Basic Checks

KNE does not have a ROIC to compare to the WACC, probably because it is not profitable.
KNE has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, KNE has more shares outstanding
The debt/assets ratio for KNE has been reduced compared to a year ago.
KNE.CA Yearly Shares OutstandingKNE.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
KNE.CA Yearly Total Debt VS Total AssetsKNE.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

2.2 Solvency

KNE has an Altman-Z score of -14.27. This is a bad value and indicates that KNE is not financially healthy and even has some risk of bankruptcy.
KNE's Altman-Z score of -14.27 is in line compared to the rest of the industry. KNE outperforms 54.55% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -14.27
ROIC/WACCN/A
WACC11.16%
KNE.CA Yearly LT Debt VS Equity VS FCFKNE.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M -4M -6M -8M -10M

2.3 Liquidity

A Current Ratio of 1.20 indicates that KNE should not have too much problems paying its short term obligations.
KNE has a Current ratio (1.20) which is in line with its industry peers.
KNE has a Quick Ratio of 1.03. This is a normal value and indicates that KNE is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.03, KNE perfoms like the industry average, outperforming 45.45% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.2
Quick Ratio 1.03
KNE.CA Yearly Current Assets VS Current LiabilitesKNE.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

2

3. Growth

3.1 Past

KNE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -815.79%.
The Revenue has grown by 20.13% in the past year. This is a very strong growth!
KNE shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.21% yearly.
EPS 1Y (TTM)-815.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-103.5%
Revenue 1Y (TTM)20.13%
Revenue growth 3Y8.98%
Revenue growth 5Y4.21%
Sales Q2Q%-95.49%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KNE.CA Yearly Revenue VS EstimatesKNE.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KNE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KNE.CA Price Earnings VS Forward Price EarningsKNE.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KNE.CA Per share dataKNE.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.01 -0 0.01 -0.01 -0.01

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KNE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KANE BIOTECH INC

TSX-V:KNE (11/14/2025, 7:00:00 PM)

0.04

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-28 2025-08-28
Earnings (Next)11-27 2025-11-27
Inst Owners0.6%
Inst Owner ChangeN/A
Ins Owners41.07%
Ins Owner ChangeN/A
Market Cap6.63M
Revenue(TTM)1.85M
Net Income(TTM)-3.32M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.59
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.01
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.01
BVpS0
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -87.22%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 25.34%
FCFM N/A
ROA(3y)28.88%
ROA(5y)-12.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.83%
GM growth 5Y3.08%
F-Score3
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 66.21%
Cap/Sales 7.31%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.2
Quick Ratio 1.03
Altman-Z -14.27
F-Score3
WACC11.16%
ROIC/WACCN/A
Cap/Depr(3y)31.77%
Cap/Depr(5y)88.96%
Cap/Sales(3y)13.66%
Cap/Sales(5y)14.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-815.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-103.5%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)20.13%
Revenue growth 3Y8.98%
Revenue growth 5Y4.21%
Sales Q2Q%-95.49%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y55.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-34.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.05%
OCF growth 3YN/A
OCF growth 5YN/A

KANE BIOTECH INC / KNE.CA FAQ

What is the fundamental rating for KNE stock?

ChartMill assigns a fundamental rating of 2 / 10 to KNE.CA.


What is the valuation status for KNE stock?

ChartMill assigns a valuation rating of 0 / 10 to KANE BIOTECH INC (KNE.CA). This can be considered as Overvalued.


Can you provide the profitability details for KANE BIOTECH INC?

KANE BIOTECH INC (KNE.CA) has a profitability rating of 2 / 10.


Can you provide the financial health for KNE stock?

The financial health rating of KANE BIOTECH INC (KNE.CA) is 2 / 10.